Literature DB >> 11118363

Induction of immune responses and break of tolerance by DNA against the HIV-1 coreceptor CCR5 but no protection from SIVsm challenge.

B Zuber1, J Hinkula, D Vödrös, P Lundholm, C Nilsson, A Mörner, M Levi, R Benthin, B Wahren.   

Abstract

An inactivating mutation in the human CCR5 gene reduces the risk of HIV-1 infection in individuals with homozygous alleles. We explored whether genetic immunization would induce an immune response directed to CCR5 structures and if immunological tolerance toward endogenous CCR5 could be broken. We also studied whether this immunization approach could protect cynomolgus monkeys from an infection, with SIVsm, which primarily uses CCR5 as a coreceptor. Epidermal but not intramuscular delivery of the CCR5 gene to mice elicited strong IgG antibody binding responses to CCR5. Intramucosal immunization of cynomolgus macaques with CCR5 DNA followed by boosts with CCR5 peptides induced prominent IgG and IgA antibody responses in serum and vaginal washings. The CCR5-specific antibodies neutralized the infectivity of primary human R5 HIV-1 strains, and the macaque SIVsm but not that of a tissue culture-adapted X4 HIV-1 strain. The consecutive CCR5 gene and CCR5 peptide immunizations induced B- and T-cell responses to peptides representing both human and macaque amino acid sequences of the respective CCR5 proteins. This indicates that tolerance was broken against endogenous macaque CCR5, which has a 98% homology to the human CCR5 gene. After the final boost, the vaccinated monkeys together with two control monkeys were challenged with SIVsm. Neither protection against nor enhancement of SIVsm infection was achieved. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11118363     DOI: 10.1006/viro.2000.0633

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  7 in total

Review 1.  Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets.

Authors:  S Phogat; R T Wyatt; G B Karlsson Hedestam
Journal:  J Intern Med       Date:  2007-07       Impact factor: 8.989

2.  Induction of mucosal and systemic antibody responses against the HIV coreceptor CCR5 upon intramuscular immunization and aerosol delivery of a virus-like particle based vaccine.

Authors:  Zoe Hunter; Hugh D Smyth; Paul Durfee; Bryce Chackerian
Journal:  Vaccine       Date:  2009-10-20       Impact factor: 3.641

3.  Specific properties of shRNA-mediated CCR5 downregulation that enhance the inhibition of HIV-1 infection in combination with shRNA targeting HIV-1 rev.

Authors:  Maria E Cardona; Jorma Hinkula; Kristin Gustafsson; Birger Christensson; Britta Wahren; Abdalla J Mohamed; C I Edvard Smith; H Jose Arteaga
Journal:  Mol Biol Rep       Date:  2022-09-12       Impact factor: 2.742

4.  A vaccine against CCR5 protects a subset of macaques upon intravaginal challenge with simian immunodeficiency virus SIVmac251.

Authors:  Koen K A Van Rompay; Zoe Hunter; Kartika Jayashankar; Julianne Peabody; David Montefiori; Celia C LaBranche; Brandon F Keele; Kara Jensen; Kristina Abel; Bryce Chackerian
Journal:  J Virol       Date:  2013-12-04       Impact factor: 5.103

5.  Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus.

Authors:  Bryce Chackerian; Lindsey Briglio; Paul S Albert; Douglas R Lowy; John T Schiller
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

6.  Allo-immunization elicits CCR5 antibodies, SDF-1 chemokines, and CD8-suppressor factors that inhibit transmission of R5 and X4 HIV-1 in women.

Authors:  Y Wang; J Underwood; R Vaughan; A Harmer; C Doyle; T Lehner
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

Review 7.  Therapeutic immunization for HIV.

Authors:  Lindvi Gudmundsdotter; Anna Sjödin; Ann-Charlotte Boström; Bo Hejdeman; Rebecca Theve-Palm; Annette Alaeus; Knut Lidman; Britta Wahren
Journal:  Springer Semin Immunopathol       Date:  2006-10-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.